Vistin Pharma ASA (FRA:VP4) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 07, 2026)


FRA:VP4 Vistin Pharma ASA FRA:VP4
80 GF Score
Price €1.79
GF Value €2.27
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vistin Pharma ASA's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:VP4 vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistin Pharma ASA Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Margin of Safety % (DCF Earnings Based) falls into.


FRA:VP4
80GF Score
Vistin Pharma ASA FRA:VP4
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistin Pharma ASA (FRA:VP4) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of €1.79 is trading 21.1% below its estimated GF Value™ of €2.27. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for FRA:VP4:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €2.27 vs. price of €1.79 (21.1% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the FRA:VP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
80GF Score

Get the complete analysis for FRA:VP4

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.79
Price
€2.27
GF Value